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Cryopreserved arterial homografts vs silver-coated
Dacron grafts for abdominal aortic infections with
intraoperative evidence of microorganisms
Theodosios Bisdas, MD, Mathias Wilhelmi, MD, Axel Haverich, MD, and
Omke E. Teebken, MD, Hannover, Germany
Objective: The gold standard for the treatment of abdominal aortic infections remains controversial. Cryopreserved
arterial homografts and silver-coated Dacron grafts have both been advocated as reasonable grafts. Direct clinical or
experimental comparisons between these two treatment options have not been published before. This study compared
cryopreserved arterial homografts and silver-coated Dacron grafts for the treatment of abdominal aortic infections in a
contaminated intraoperative field.
Methods: From January 2004 to December 2009, 56 patients underwent in situ arterial reconstruction for an abdominal
aortic infection. Patients with negative intraoperative microbiologic specimens were excluded. We compared 22 of 36
patients (61%) receiving cryopreserved arterial homografts (group A) vs 11 of 20 (55%) receiving a silver-coated Dacron
graft (group B). Primary outcomes were survival and limb salvage; secondary outcomes were graft patency and
reinfection. Direct costs of therapy were also calculated.
Results: Thirty-day mortality was 14% in group A and 18% in group B (P >.99), and 2-year survival rates were 82% and
73%, respectively (P  .79). After 2 years, limb salvage was 96% and 100%, respectively (P  .50), whereas graft patency
was 100% for both groups. Major complications were an aneurysmal degeneration in group A and graft reinfection in
group B (n  2). Median direct costs of therapy (in US $) were $41,697 (range, $28,347-$53,362) in group A and
$15,531 (range, $11,310-$22,209) in group B (P  .02).
Conclusions: Our results show comparable effectiveness between cryopreserved arterial homograft and silver-coated
Dacron graft in the contaminated operative field with respect to early mortality and midterm survival. Graft-inherent
complications, aneurysmal degeneration for homografts, and reinfection for silver graft, were also observed. The in situ
arterial reconstruction with homografts is nearly three times more expensive than with silver graft. ( J Vasc Surg 2011;
53:1274-81.)
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tThe changing epidemiology of vascular infections, with
increased evidence of highly virulent microorganisms (eg,
Pseudomonas aeruginosa), has made the in situ revascular-
ization after arterial or prosthetic graft excision in the
setting of infection a challenging surgical task associated
with considerable mortality rates of 20% to 75%.1,2 Several
grafts and surgical approaches have been developed to gain
long-term durability, a less-traumatic surgical procedure,
and the prevention of infection recurrence.1 The standard
of care advocated frommost surgeons remains the proximal
and distal ligation of the abdominal aorta and the implan-
tation of an extra-anatomic axillobifemoral prosthetic by-
pass.1 Antibiotic-bonded grafts (eg, rifampin-bonded Da-
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1274ron graft)3 and superficial femoropopliteal veins4 have
een considered as durable alternatives as well.
Recent studies have presented the silver-coated Dacron
raft (SCG) as a reasonable option for treatment of abdom-
nal aortic infection (AAI) treatment. The availability of the
raft and the relatively low rates of initial secondary proce-
ures are its important advantages.2 From the other side,
here has been a renewed interest in the cryopreserved
rterial homograft (CAH) for the treatment of vascular
raft infections, with favorable outcomes even against
ighly virulent microorganisms.5-9 However, SCG and
AH are associated with specific early or late complications
uch as aneurysmatic degeneration, occlusion, and reinfec-
ion.1,2,5
Because of the small number of recognized aortic
graft) infections and priorities for graft selection and local
reatment at single institutions, most publications deal only
ith small numbers of patients.1,2 In addition, the very low
revalence of vascular graft infections (3%)1,10 impedes a
tatistically reasonable comparison of different graft mate-
ials in a randomized controlled trial.11 For example,
3000 patients are needed to address a statistically signif-
cant reduction from 4% to 2% of infection recurrence rates.
either national health care agencies nor the device indus-
ry are likely to get involved in such a large multicenter
tudy at present.
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Volume 53, Number 5 Bisdas et al 1275As a consequence, we initiated a study to retrospec-
tively compare the effectiveness of CAH vs SCG, trying to
assess a first trend. Here, the short-term and medium-term
outcomes using CAH or SCG for the in situ reconstruction
of the infected abdominal aorta were documented. We
hypothesized that the postoperative outcomes would favor
CAH, because the elimination of the infectious focus seems
more likely in the absence of alloplastic material.
MATERIALS AND METHODS
The study design and the follow-up protocol were
approved by the local Ethics Committee (No. 660/2010/
01/22).
Patients. A retrospective review of our prospectively
collected data for AAI from January 2004 through Decem-
ber 2009 identified 56 patients undergoing in situ recon-
struction of the abdominal aorta after suspicion or diagno-
sis of vascular infection. To compare both grafts in a
uniform and, more important, contaminated environment,
only patients with positive intraoperative microbiologic
specimens were included. Thus, 22 of 36 patients (61%)
undergoing CAH implantation (group A) and 11 of 20
patients (55%) undergoing SCG implantation (group B) in
the abdominal aorta were considered. Patient characteris-
tics and comorbidities are reported in Table I.
Indications for CAH or SCG implantation.
Indications for surgery were (1) prosthetic graft infections,
(2) prosthesis-enteric (PEF) or prosthesis-ureter fistulas
(PUF), and (3) infected aneurysms. The choice of CAH or
SCG was constricted due to the limited availability of CAH
in case of emergency but was left to the surgeon’s discre-
tion. Details regarding CAH preparation and the charac-
teristics of SCGs have been described elsewhere.2,5-7,11
Surgical procedure and treatment adjuncts. The
surgical technique has been described in previous re-
ports.5-7 Patients in both groups underwent complete de-
bridement of the surrounding tissues, followed by irriga-
tion of the operative fields with liberal amounts of 7.5%
standard povidone-iodine solution (Braunol, B. Braun,
Melsungen, Germany) diluted in 0.9%-isotonic NaCl. Both
grafts were washed in 5000 IU neomycin/250 IU bacitra-
cin solution (Baneocin pro instillatione, Sandoz, Kundl,
Austria) for at least 5 minutes. In nonemergency patients
with prosthetic graft infection (PGI), PEF, or PUF, a
ureteral splint (J-catheter) was implanted preoperatively to
enable better recognition of the ureters for safe debride-
ment of infected tissues. All patients received standard
intraoperative antibiotic therapy with cefuroxime. Intraop-
erative specimens of tissues and excised prosthetic grafts
were sent for microbiologic and histologic examination.
Postoperative management and follow-up exa-
mination. Intravenous antibiotics were administered dur-
ing the parenteral nutrition, and oral administration of
organism-specific oral antibiotics was continued for at least
2 weeks after discharge.13 Caloric requirements were deliv-
ered orally as soon as feasible.
All patients were seen in our department 3 and 6
months after surgery and biannually thereafter. Postopera- cive outcomes were evaluated with ultrasound imaging or
omputed tomography scan. We also contacted our pa-
ients by telephone to obtain information about late com-
lications at the time of analysis.
Definitions. The criteria of Centers for Disease Con-
rol and Prevention (CDC) were used to define PGI.14 All
adiologic findings were evaluated separately by an experi-
nced independent radiologist and two vascular surgeons.
n infected aortic aneurysm was defined as aortic dilation
ith a diameter of 3 cm, on the basis of clinical evidence
f infection by fever and leukocytosis in accordance with
DC criteria and periaortic soft-tissue infiltration demon-
trated by contrast-enhanced CT scan.15
Study design. Group Awas compared with group B in
omorbidities, preoperative clinical condition as deter-
ined by the American Society of Anesthesiologists (ASA)
core, and operation time to exclude any undue differences
hat might introduce bias. Primary outcomes were survival
nd limb salvage. Secondary outcomes were reinfection (ac-
ording to CDC criteria) and graft patency. Perioperative
able I. Patient demographics, comorbidities, and
reoperative characteristics
ariable
Group A Group B
P
No. or
mean  SD
No. or
mean  SD
otal 22 11
ender
Male 21 11
Female 1 0 .99
ge, years 68  8 61  16 .16
omorbidity
Hypertension 15 (68) 6 (55) .47
COPD 4 (18) 4 (36) .39
Coronary disease 10 (45) 4 (36) .71
Myocardial infarction
6 months
4 (18) 3 (27) .66
Hypercholesterolemia 6 (27) 3 (27) .99
Diabetes mellitus 6 (27) 4 (36) .69
ody mass index,
kg/m2
24.7  3.51 22.8  3.50 .16
KD-EPI GFRa 69.59  31.62 69.54  26.35 .99
ialysis 2 (9) 1 (9) .99
SA score
II 1 (5) 1 (9)
III 14 (63) 4 (36)
IV 6 (27) 5 (46) .37
V 1 (5) 1 (9)
ositive pre-op
bloodstream
cultures
5 (23) 1 (9) .63
ntibiotic pre-op
treatment
14 (64) 5 (46) .45
SA, American Society of Anesthesiologists; CKD-EPI, Chronic Kidney
isease Epidemiology Collaboration; COPD, chronic obstructive pulmo-
ary disease; GFR, glomerular filtration rate; SD, standard deviation.
The CKD-EPI GFR is an estimate of the glomerular filtration rate using
erum creatinine and demographic factors. It is a relatively new equation
roposed to be superior to the Modification of Diet in Renal Disease GFR
quation.12omplications and cost-effectiveness were also addressed.
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May 20111276 Bisdas et alStatistical analysis. All analyses were performed and
graphs were created with MedCalc 9.4.2.0 software (Mari-
ankerke, Belgium). Categoric variables are presented as
percentages. Normally distributed continuous variables are
presented as mean  standard deviation and the respective
not normally distributed are presented as medians with the
interquartile range. The distribution of continuous vari-
ables was determined by Kolmogorov-Smirnov test. Ordi-
nal data with two categories were compared with Pearson
2 test and with more than three categories (eg ASA score)
with 2 for trend. Normally distributed continuous vari-
ables were compared with the t test for independent vari-
ables, and the Mann-Whitney test was performed for the
respective not normally distributed data. Survival, limb
salvage, and graft patency rates were calculated using the
Kaplan-Meier method. Hazard ratios (HR) are presented
with 95% confidence intervals (CIs). Patients were censored
at their last known date of follow-up. A value of P .05 was
considered statistically significant for individual tests.
RESULTS
Indications for surgery in group A were PGI in 8, PEF
in 10, PUF in 1, and infected aneurysms in 3 patients.
Comparably, indications in group B were PGI in 1 (P 
.21), PEF in 2 (P  .13), and infected aneurysms in 8
patients (P .001). A synopsis of symptoms at the time of
presentation, CT scan findings, responsible microorgan-
isms and outcomes is presented in Table II (online only).
The most common microorganisms in group A were
Staphylococcus aureus, Enterococcus faecalis, and E faecium
(18% each one). Methicillin-resistant S aureus (MRSA) was
found in three patients (14%) and P aeruginosa in two
patients (9%). In group B, the most common agents were P
aeruginosa, S epidermidis, and Escherichia coli (18% each
one). MRSA was found in one patient (9%).
Eight patients (36%) in group A and seven patients in
group B (64%) underwent an urgent operation (P  .26)
without any cardiac resuscitation. Purulent tissues were
found intraoperatively in 11 patients (50%) in group A and
in 2 patients (18%) in group B (P  .13). Aortic graft
configurations in group Awere aortic tube grafts in 5 (23%)
aortobiiliac in 6 (27%), aortobifemoral in 5 (23%) and
aortobiprofundal in 6 (27%). The configurations in group
B were aortic tube graft in 5 (45%), aortobiiliac in 5 (45%),
and aortobifemoral in 1 (10%). Preoperative ureteral splint-
ing was required in 10 patients in group A (45%) and in 1
patient in group B (10%). No patients sustained a ureter
injury.
Mean duration of operation was 279  96 minutes in
group A and 172 60minutes in group B (P .001). The
median number of blood cell components administrated
during the operation was 8 (range, 5.75-10.25) in group A
vs 6 (range, 4.25-7.50) in group B (P  .56).
Mean length of hospital stay amounted to 24 14 days
in group A and to 16 12 days in group B (P .06). The
30-day mortality was 14% (3 of 22 patients) in group A and
18% (2 of 11 patients) in group B (P .99). Sepsis-related
multiple organ failure (MOF) was the cause of death in –oth groups (Patients 1, 2, 20, 32, 33; Table II, online
nly). In-hospital mortality was 14% in group A and 27% (3
f 11 patients: 24, 32, and 33) in group B (P  .38).
erioperative complications are presented in Table III.
raft-related complications were observed in two patients
n each group (group A: 9% vs group B: 20%, P .57). No
atients died of a graft-related complication.
Mean follow-up was 27 21.5 months in group A and
8 18.7 months in group B (P .24). Except for patient
3, who died of sepsis-related heart failure in the interme-
iate care unit on the same day, all patients were included in
he follow-up surveillance (Table II, online only). The
ostoperative survival rates are illustrated as a Kaplan-Meier
urve in Fig 1. Two-year survival rates were 82% in group A
nd 73% in group B (HR, 0.82; 95% CI, 0.26-5.64; P 
80). Reasons for late (30 days) death in group A were
yocardial infraction in patients 7 and 13 and sepsis-
elatedMOF due to endocarditis in patient 21. In group B,
atient 25 died of late sepsis-related MOF. This patient
nderwent SCG implantation 5 months after heart trans-
lantation to treat a contained rupture of a 10-cm common
liac aneurysm. He was taking immunosuppressants, and P
eruginosa septicemia was documented before the aneu-
ysm rupture.
The 2-year limb salvage rate was 96% in group A and
00% in group B (P  .50), and 2-year graft patency
mounted to 100% for both groups. However, the cumu-
ative graft patency rates decreased to 75% for group B (P
09) after 3 years.
Evidence of reinfection (ongoing or recurrent) was
aised in no patients in group A and in two patients (20%) in
roup B (P  .09). Patient 25, diagnosed with spondylo-
iscitis and HIV infection, underwent a 18fluorodeoxyglu-
ose (FDG) positron-emission tomography (PET) com-
uted tomography (CT) scan 39 months postoperatively.
he examination showed an increased 18FDG uptake
maximum standardized uptake value, 6.0) around the
CG (Fig 2). A CT-guided perigraft fluid aspiration in
009 showed evidence of Mycobacterium avium; this mi-
roorganism was found also in the intraoperative speci-
ens. The patient complained of persistent back pain but
as rejected any further surgical intervention. Long-term
uberculostatic treatment has been initiated instead. Patient
0 presented with a graft-enteric fistula on postoperative
ay 19 with evidence of E coli. This patient underwent a
AH implantation and had an uneventful postoperative
ourse.
The treatment costs from admission to discharge were
alculated in each group and compared to the reimburse-
ent according to diagnosis-related group. Median direct
osts of therapy (in US $) were $41,697 (range, $28,347-
53,362) in group A and $15,531 (range, $11,310-
22,209) in group B (P  .02). More interestingly, the
edian contribution margin was –$13,272 (range,
$16,790 to –$5,065) in group A and $1290 (range,
$24,372 to $12,975) in group B (P  .01).
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SCGs showed comparable 2-year survival and limb
salvage rates compared with CAHs. The one observed limb
Fig 1. Kaplan-Meier life-table analysis comparing the
abdominal aorta with cryopreserved arterial homografts
standard error (SE) is10% in group A at 1.2 months, 11
B at 0.01 months, 12% at 0.56 months, and 13% at 2 m
Table III. Perioperative complications and respective trea
Complications
Group A: Cryopreserved arterial homografts
Graft related
Anastomotic bleeding Reoper
Aneurysmatic degeneration Homo
Operation related
Hematoma Open s
Spleen rupture Splenec
Pancreatitis (necrotizing) Duode
Wound infection (lymphocele) Vacuum
Other
Acute limb ischemiab Tibial a
Atrioventricular block, 3rd degree Heart p
Cholecystitis Cholec
Group B: Silver-coated Dacron graft
Graft related
Occlusion Throm
Prosthetic-enteric fistula CAH i
Operation related
Wound dehiscence Wound
Cardiac arrest Cardiac
Pancreatitis Relapa
Other
Cholecystitis Cholec
Visceral ischemia Aortov
CAH, Cryopreserved arterial homograft.
aV.A.C Therapy Unit; KCI Concepts, San Antonio, Tex.
bCaused by high rates of catecholamines (septic shock).loss in group A was caused by limb ischemia related to high (oses of catecholamines in a patient with severe septic
hock. Regarding the secondary end points, we observed
onsiderable higher reinfection rates in the SCG group
ival rates after in situ reconstruction of the infected
up A) and silver-coated Dacron grafts (group B). The
36 months, and 12% at 37 months. SE is10% in group
.
t for each group
Treatment No. (%)
and repair 1 (5)
reconstruction with Dacron patch 1 (5)
al drainage/temporary abdominal closure 2 (9)
2 (9)
ncreatectomy 1 (5)
isted wound closurea 1 (5)
tation on both sides 1 (5)
aker implantation 1 (5)
tomy 1 (5)
my 1 (9)
tation 1 (9)
ir 2 (18)
scitation 1 (9)
y with drainage 1 (9)
tomy 1 (9)
l bypass 1 (9)surv
(gro
% attmen
ation
graft
urgic
tomy
nopa
-ass
mpu
acem
ystec
becto
mplan
repa
resu
rotom
ystec
iscera20%), whereas no evidence for reinfection was raised in the
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May 20111278 Bisdas et alCAHgroup during surveillance. Patency was 100% in CAH
and 75% in SCG after 3 years. In the CAH group, aneurys-
mal degeneration was the major complication. Any addi-
tional subclinical aneurysmal degeneration was excluded
using duplex ultrasound imaging and contrast-enhanced
CT scans. Major complications in the SCG group were an
early PEF and a late graft occlusion.
Encouraging outcomes have been reported with both
grafts.1-5,8 However, almost all publications represent ob-
servational studies with only one type of treatment, and the
definition of graft infection in these studies is debatable
because they also included patients with negative intraop-
erative microbiologic specimens.1-9 In contrast, the present
study is the first, to our knowledge, to compare two differ-
Fig 2. 18Fluorodeoxyglucose positron-emission tomog
ongoing infection of the silver-coated graft caused by c
responsible microorganism.ent graft types for AAI treatment. Although the method Seads to a decreased sample size, we included only patients
ith a bacterial graft or arterial infection documented by
ositive microbiologic specimens, resulting in an objective
omparison between the grafts. Some of the data for group
patients were reported previously in our single-center
-year experience with CAH.5
Looking carefully at the indications for operation, there
ere more PGIs and PEFs in group A, whereas most group
patients presented with an infected aneurysm. This fact
eflects our previous institution policy regarding the graft
hoice. We preferred CAH implantation in patients with
he diagnosis of AAI without an acute life-threatening
tatus (eg, gastrointestinal bleeding, free aneurysm rupture,
ardiogenic shock). Most patients in group B underwent
-computed tomography scan of patient 25 shows the
mitant spondylodiscitis. Mycobacterium avium was theraphy
oncoCG implantation due to an unexpected intraoperative
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Volume 53, Number 5 Bisdas et al 1279field with suspicion of infection (eg signs of purulence,
contained rupture with preoperative clinical signs of infec-
tion, spondylodiscitis, nondiagnosed fistula; Table II, on-
line only) or due to an urgent operation and unavailable
CAH. Also noteworthy is the longer mean operation time
in group A (P .001), which was most likely related to the
higher proportion of PGI and PEF in group A. Adhesiolysis
and precise debridement of the infected tissues extend the
operation time significantly.
Our results rejected our hypothesis that patients under-
going total removal of any artificial material show better
outcomes and support the theory that in case of vascular
arterial infection, there is no gold standard for treatment
between CAH and SCG. All types of available grafts and
techniques (vein grafts, CAHs, SCGs, antibiotic-bonded
grafts, extra-anatomic bypass) have drawbacks.1 Especially
regarding CAH and SCG, it is well-known that CAH have
a risk of aneurysmal degeneration, although the exact
mechanism is a matter of debate and has been discussed
extensively in other reports.1,2,5,7 SCG patients are said to
exhibit high rates of recurrent or ongoing infections.2,16
Both complications were observed in our study popula-
tions.
Another important issue remains the costs of therapy.
To our knowledge, we are the first to calculate the costs of
treatment, including all events during the postoperative
course, for both groups. Interestingly but as expected,
CAH treatment costs were notably and statistically signifi-
cantly higher than costs in group B. Although costs of
therapy should not influence the quality of a patient’s
treatment and the surgeon’s strategy when one treatment is
superior to another, this issue should be given serious
consideration in cases of comparable effectiveness between
different types of therapy.
In the literature, autogenous veins remain the most
effective method to avoid any reinfection. Important fac-
tors limiting their applicability are extended surgical trauma
(risk of wound infection) and longer operation time.1,2,4
CAH are associated with lower rates of reinfection (no
evidence of reinfection in our study), but limited availabil-
ity and durability remain their drawbacks. Our study also
adds the costs of therapy as a main disadvantage.1,2,5 Late
dilation rates amounted to 17% (5% in our study) and late
occlusion rates to 32% (0% in our study).2 In contrast, a late
occlusion was observed in the SCG group, although pros-
thetic grafts rarely led to late occlusions.2 An important risk
factor for graft occlusion remains the distal flow path,
especially in aortofemoral and small-caliber grafts.17
SCG failed to prevent graft infection in several clin-
ical and experimental studies, and the risk of reinfection
remains a concern.2,15,18,19 Its availability in different
types and sizes, its ease of use, its durability, and the
lower costs (vs CAH due to our results) remain impor-
tant advantages.2,15
Finally, the use of extra-anatomic bypass and antibiotic-
bonded grafts as reasonable treatment options has been
challenged from recent studies, respectively, due to the
considerable reinfection rates and to the development of dntibiotic resistance with graft failure.1,2 Interestingly how-
ver, is that antibiotic-bonded grafts (mostly rifampin-
onded) were more effective at preventing graft infection
ompared with SCG (polyester prosthesis) in experimental
tudies.18
Consequently, the successful treatment of AAI depends
n a variety of parameters and factors and not only on the
hoice of the most effective graft. The patient’s condition,
omorbidities, appropriate antibiotic treatment, precise in-
ectious tissue debridement, and intra-abdominal lavage are
qually important contributors.
Antibiotic treatment is mostly organism-specific. It is
oteworthy that no guidelines are available for this issue,
nd it remains to be addressed.13 It is proposed, generally,
hat when the diagnosis of vascular graft infection is obvi-
us, empiric broad-spectrum parenteral therapy should
e instituted rapidly before the initial surgical explora-
ion or reconstruction.13 The most-preferred antibiotic
gents are daptomycin for gram-positive coverage coupled
ith piperacillin-tazobactam, cefepime, or levofloxacin for
ram-negative coverage.13,20 Vancomycin or linezolid (we
refer linezolid)5 is an alternative for staphylococcal and
RSA coverage.
Patients with invasive or cavitary infections and those
reated by in situ replacement (prosthetic or allograft) or
raft preservation techniques require 4 to 6 weeks of par-
nteral antibiotics.11We prefer switching the patient to oral
dministration early, if his or her general condition allows it
nd the clinical chemical inflammation parameters have
ormalized or greatly improved, particularly if the active
ubstance has high oral bioavailability (eg fluoroquinolo-
es, clindamycin, and linezolid). A randomized trial for
bdominal infections showed that conversion of intrave-
ous antibiotic therapy to oral administration appears as
ffective as continued intravenous therapy.21 Several insti-
utions augment therapy by using antibiotic-loaded beads
n their wound sterilization algorithm.11
Finally, the role of a thorough debridement of all
nfectious tissues with irrigation of the operative field with
iberal amounts of antiseptic or antibiotic agents (in this
tudy, povidone-iodine solution) remains decisive. Differ-
nt agents have been examined in similar intra-abdominal
peritonitis-associated) infections in general surgery but
ot in vascular infections.22-28 A number of clinical and
any experimental studies showed a decrease of infectious
omplications and death after irrigation with solutions con-
aining antibiotics.22,23 A current meta-analysis addresses
he superior value of antibiotics in lavage in experimental
eritonitis, although the authors recognize the interval
etween the onset of an experimental peritonitis and the
tart of lavage treatment was usually only 1 or 2 hours,
hich is not representative of the clinical situation.23
The effectiveness of antiseptic agents such as povidone-
odine and chlorhexidine in this setting is a matter of
ebate. Toxic effects on host peritoneal cells led to a
ignificant increase in death, whereas another study ob-
erved that povidone-iodine solutions enhanced peritoneal
efense mechanisms.25-27 In a prospective randomized
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May 20111280 Bisdas et alstudy,28 however, the use of diluted povidone-iodine solu-
tion as an intraperitoneal irrigant was significantly superior
to saline irrigation in preventing the development of intra-
abdominal abscesses.
In our opinion, important treatment adjuncts are also
(1) ureteral drainage for safe debridement of infectious
tissues and (2) the impregnation of the grafts with neomy-
cin, a bactericide antibiotic (transfer of the antibiotic to the
perigraft tissues and prevention of graft colonization with
microorganisms).5 CAHs may thus have an enhanced in-
herent antimicrobial activity compared with conventional
grafts because they are stored in antibiotic solution, and this
remains a great advantage.5,6 Both antibiotic loading and
neomycin impregnation could explain the absence of any
reinfection in the respective group.
Taking under consideration all of the aforementioned
factors, we strongly suggest that antibiotic treatment and
intra-abdominal lavage are prerequisites for successful
treatment. Guidelines for “best medical treatment” are
mandatory. Our treatment algorithm is presented in Fig 3.
Although the effectiveness of SCG in PGI or fistulas (few
cases in the respective group) is not clearly demonstrated in
this study, SCG seem a reasonable therapy for an infected
aneurysm. We still favor CAH, despite the financial disad-
vantage, in cases of highly virulent microorganisms. How-
ever, we propose the use of SCG as a primary treatment in
hospitals that have no access to a tissue bank or are not
Fig 3. Schematic presentation of the algorithm we usedfamiliar with this technique. CWe recognize further limitations of this single-center
ork. The retrospective design and the limited number of
atients in both groups reduce the statistical power of the
esults and may introduce bias. Although abdominal aortic
neurysms may be contaminated without signs of infec-
ion,29 infection in this study was confirmed through a
ombination of clinical, radiologic, and intraoperative signs
f infection (Table II, online only) and in accordance with
he CDC criteria.
Although we included only patients with contaminated
ntraoperative specimens to reduce heterogeneity, the indi-
ations were still very different between the two groups.
owever, this work represents a first attempt to derive
nformation about the most efficient graft material in sim-
lar microbiologic circumstances.
Finally, the results may not apply to all cases of aortic
nfection, and several situations might arise in which nei-
her of these techniques is optimal; for example, a neoaortic
econstruction using autogenous femoral vein in a young
ealthy patient may be preferential.
ONCLUSIONS
The results of this study showed comparable outcomes
etween CAH and SCG for the treatment of AAI with
ositive evidence of microorganisms. Major complications
ere aneurysmatic degeneration for CAH and reinfection
or SCG. The costs of therapy were significantly higher for
e treatment of vascular infections of the abdominal aorta.AH. To improve outcome in these patients, important
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2
2
2
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Volume 53, Number 5 Bisdas et al 1281treatment adjuncts such as perioperative antibiotic therapy,
tissue debridement, and intra-abdominal lavage must be
taken under consideration and should be extensively inves-
tigated in future studies. Furthermore, a close follow-up
schedule enables detection of graft inherent complications
such as aneurysmal degeneration in homografts.
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ery, symptoms at the time of presentation, computed tomography findings, responsible microorganisms,
urvival for each patient
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y
CT scan, endoscopy and
intraoperative findings Microorganisms
Specific intra-op characteristics
and reoperations (30 days) Last follow-up
in CR femoral anastomoses
(aortobifemoral graft)
S aureus None POD 15a
Upper GI endoscopy:
PEF
C freundii, Enterococcus
spp, S epidermidis,
S anginosus
Intra-op: Partial resection of
duodenum
POD 27a
Reoperations:
POD 1: Splenectomy (spleen
rupture)
POD 8: Cholecystectomy
(acute cholecystitis)
POD 9: Total
duodenopancreatectomy
(acute necrotizing
pancreatitis),
choledochostomy
CR spondylodiscitis P aeruginosa None 59 months alive
raft
stal
E aerogenes Massive adhesions 55 months alive
th Abscess around the
graft, suspicion of
spondylodiscitis
E faecalis, S
haemolyticus
Temporary abdominal closure
(uncontrolled bleeding
tendency)
54 months alive
Reoperation:
POD 1: Abdominal closure
POD 2: Heart pacer
implantation (AV block
III°)
Expanding perigraft
fluid with gas,
infection of aortorenal
bypass
Bacteroides spp, E coli,
E faecalis, E faecium
Nephrectomy (left kidney
without function)
36th montha
Splenectomy (splenic rupture
due to splenomegaly)
ht
e of
Occlusion of right graft
branch and deep
abscess in right
femoral anastomosis
S aureus, E cloacae POD 11: Open surgical
drainage of hematoma
49 months alive
a, CR spondylodiscitis,
abscess in upper limb
S typhimurium None 45 months alive
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1281.e1Table II (online only). Summary of indications for surg
intraoperative characteristics, reoperations and midterm s
Patient Graft Diagnosis
Symptoms, indications
relevant medical histor
Group A (Cryopreserved arterial homografts)
1 CAH PGI Fever, acute bilateral gro
pain
2 CAH PEF Acute abdominal pain,
Hb6 g/dL
3 CAH IA Back pain
4 CAH PEF Upper GI bleeding,
laparotomy for (1) Y-g
due to type I endoleak
after EVAR and (2) di
Roux-Y gastric bypass
5 CAH PGI Wound dehiscence in bo
femoral regions, fever,
leucocytosis
6 CAH PEF Leucocytosis, weight loss
7 CAH PGI Wound dehiscence in rig
femoral region, acute
ischemia, wet gangren
right limb
8 CAH IA Upper left limb hematom
leucocytosis
Table II (online only). Continued.
,
y
CT scan, endoscopy and
intraoperative findings Microorganisms
Specific intra-op characteristics
and reoperations (30 days) Last follow-up
Expanding perigraft
fluid with gas
Streptococcus Partial ileum resection 49 months alive
th
Expanding perigraft
fluid with gas,
intraoperative
diagnosis of fistula
E faecium None 53 months alive
Psoas abscess L rhamnosus, E cloacae,
E coli
POD 4: Anastomotic bleeding
of homograft, partial
duodenum resection
38 months alive
POD 5: Tibial amputation on
both sides (patient in severe
septic shock with high rates
of administrated
catecholamines)
POD 9: Wound repair
(dehiscence of amputation
wound)
sis
Expanding perigraft
fluid with gas
S aureus Limited excision of the
infected graft (high
perioperative risk – stroke,
dialysis, prostate Ca,
coronary artery disease)
37th montha
ent
ure
Upper GI endoscopy E. faecium 34 months alive
Upper GI endoscopy Propionibacterium spp,
CNS, S sanguinis
23rd month: Homograft
reconstruction with Dacron
patch (aneurysmatic
degeneration of the left
homograft-femoral
anastomosis)
30 months alive
in
ed
Expanding perigraft
(silver-coated) fluid
with gas; intra-op
diagnosis of fistula
MRSA, E faecalis, K
pneumoniae, E coli
None 6 months alive
Psoas abscess-fistula,
intra-op diagnosis
S aureus, S anginosus None 13 months alive
18FDG PET-CT
(SUVmax: 18)
MRSA, P aeruginosa, K
pneumoniae, P
mirabilis, C albicans
Explantation of occluded
femoro-popliteal bypass
(artificial material)
18 months alive
POD 24-36: VAC therapy:
Wound dehiscence
(lymphocele) in upper limb
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B
isdasetalPatient Graft Diagnosis
Symptoms, indications
relevant medical histor
9 CAH PEF Abdominal pain, fever,
leucocytosis
10 CAH PGI Abdominal pain, fever,
leucocytosis; pain in bo
femoral regions
11 CAH PEF Lumbago, leucocytosis,
anemia
12 CAH PGI Skin redness in femoral
region, fever, leucocyto
(patient was admitted
initially suffering from
stroke)
13 CAH PEF Upper GI bleeding , urg
endovascular stent
implant and fistula clos
(10 days before CAH
implantation)
14 CAH PEF Upper GI bleeding
15 CAH PEF Ileus (urgent laparotomy
external hospital show
purulence)
16 CAH PEF FUO
17 CAH PGI FUO, laparotomy for
sigmoid diverticulitis,
septicemia (MRSA)
,
y
CT scan, endoscopy and
intraoperative findings Microorganisms
Specific intra-op characteristics
and reoperations (30 days) Last follow-up
sis
Expanding perigraft
fluid with gas
S epidermidis, S
haemolyticus
None 4 months alive
Expanding perigraft
(silver-coated) fluid
with gas
S maltophilia, C krusei None 6 months alive
Suspicion for graft-
ureter fistula
E faecium, E faecalis, C
albicans
Left cutaneous ureterostoma POD 30a
POD 1: Rectal resection (4-
cm rectal cancer)
nd
CR in duodenum, psoas
abscess, dissection of
abdominal and iliac
arteries
MRSA None POD 33a
a,
ies
Expanding perigraft
fluid with gas
S epidermidis Explantation of the
femoropopliteal bypass
5 months alive
CT scan nonspecific-
intra-op diagnosis of
CR spondylodiscitis
Corynebacterium spp None 46 months alive
CR of 10-cm iliac
aneurysm
P aeruginosa None 2nd montha
CR– intraoperative
diagnosis of infection
M avium Isolated organ perfusion 36 months alive
Occlusion of left
common iliac artery,
intraoperative
diagnosis of
aortoenteric fistula
P aeruginosa, CNS None 48 months alive
sia
CR of the aneurysm in
left psoas muscle,
occlusion of left
external iliac artery
C. fetus fetus 24th month: Thrombectomy
of left graft branch and iliac-
femoral bypass with SCG
(occlusion of the left SCG
branch)
30 months alive
Nonspecific CT findings
intraoperative
findings: Massive
adhesions
E coli POD 13: Relaparotomy with
drainage (pancreatitis and
wound dehiscence)
5 months alive
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Patient Graft Diagnosis
Symptoms, indications
relevant medical histor
18 CAH PGI Skin redness in femoral
region, fever, leucocyto
19 CAH PEF FUO
20 CAH PUF Acute massive
macrohematuria
21 CAH IA Lumbago, concomitant
endocarditis of aortic a
mitral valve, septicemia
(MRSA)
22 CAH PGI Acute right limb ischemi
multiple thrombectom
of right graft branch
(femoropopliteal I
bypass), fever,
leucocytosis
Group B (silver-coated Dacron graft)
23 SCG IA Asymptomatic
24 SCG IA Fever, leucocytosis,
septicemia,
immunosuppressive
therapy (heart
transplantation)
25 SCG IA Lumbago, HIV therapy
26 SCG PEF Critical ischemia of left
limb, abdominal pain,
laparotomy for rectal
cancer 1 year ago
27 SCG IA Abdominal pain, fever,
leucocytosis, paraesthe
of left limb, hepatitis B
and C, i.v. drug abuse
28 SCG IA Fever, leucocytosis
(nephrectomy for
pyelonephritis 2 weeks
ago)
,
y
CT scan, endoscopy and
intraoperative findings Microorganisms
Specific intra-op characteristics
and reoperations (30 days) Last follow-up
Occlusion of left iliac
branch, perigraft fluid
S epidermidis Suprarenal clamping (5 min) 6 months alive
n
),
CR, intraoperative
diagnosis
E. coli POD 19: In situ
reconstruction with CAH
(Pat No15), explantation of
SCG (PEF)
6 months alive
Not specific CT
findings-
intraoperative
diagnosis- massive
adhesions
E faecalis POD 8: Relaparotomy and
wound repair (fascia and
wound dehiscence)
23 months alive
b- Type A dissection,
cholecystitis, free
rupture of abdominal
aorta
E faecalis, S epidermidis Cholecystectomy
(cholecystitis), temporary
abdominal closure
POD 17a
POD 1: Second-look
laparotomy, mini-
thoracotomy (hemothorax)
POD 2: Second-look
laparotomy
POD 5: Aortovisceral bypass
(visceral ischemia caused by
the dissection membrane)
POD 12: Wound closure
(laparotomy)
Diagnosis of PEF in
upper GI endoscopy
and CT scan
MRSA Intraoperative cardiac
resuscitation
POD 1a
ococci; CR, contained rupture; CT, computed tomography; EVAR, endovascular (infrarenal) aortic repair; 18FDG-PET, fluorodeoxyglucose
estinal; IA, infected aneurysm; Hb, hemoglobin; MRSA, methicillin-resistant Staphylococcus aureus; prosthetic-enteric fistula; PGI, prosthetic
la; SCG, silver-coated graft.
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Patient Graft Diagnosis
Symptoms, indications
relevant medical histor
29 SCG PGI Fever, leucocytosis, acute
ischemia of left limb,
urinary tract infection
30 SCG IA Abdominal pain, unknow
Hb decrease (7 g/dL
pleura empyema
31 SCG IA No specific symptoms,
severe ocular infection
(endophthalmitis)
32 SCG IA Acute abdominal pain, H
decrease, leucocytosis,
fever
33 SCG PEF Upper GI bleeding
CAH, Cryopreserved arterial homograft; CNS, coagulase-negative staphyl
positron-emission tomography; FUO, fever unknown origin; GI, gastroint
graft infection; POD, postoperative day; PUF, prosthetic urinary tract fistu
aIndicates the patient died.
